Moving the Future of Childhood Cancer Research

At the end of 2022, the Children’s Cancer Therapy Development Institute (cc-TDI) will relocate to a newly expanded, high-tech laboratory in nearby Hillsboro, Oregon; increasing our capabilities and allowing our team to build on the exciting momentum established through seven years of hard work and your crucial support.  The new 7,000+ sq ft state-of-the-art laboratory will support the growth and expansion of our collaborative scientific team and our continuing mission: to make childhood cancer universally survivable.  Every child’s life deserves hope, and we’re leaving no one behind as we move the future of childhood cancer research!

Our resolve is inspired by the bravery of our children and the fact that, despite the enormous progress made in cancer research, cancer is still the leading disease-related cause of death in children in the United States.  Although over 15,000+ children are diagnosed with cancer every year, current norms for research investment do not prioritize childhood cancer due to relatively small patient populations.  In fact, only 9 drugs have received primary FDA approval for the use in children since 1978.  This is why your support is critical to our mission. Motivated by science-justified hope since our inception in 2015, cc-TDI remains committed to developing safe and effective treatment options by translating scientific discovery into clinical trials for underserved childhood cancers.

Thanks to you, our dedicated community, cc-TDI’s work has had an auspicious launch of shared successes, including two drugs achieving three national and international trial status for children, 58 new scientific publications, and a myriad of cutting-edge discoveries in understanding the biology of complex childhood cancers.  Working in global collaboration with experts in the field, our team of biologists and engineers have established a time and cost-saving pipeline for delivering safe, effective drugs to clinical trials. Our goal is to make 5 drugs available for children via trials each and every year!

To celebrate and build upon your generous support, we are commencing a $1,000,000 expansion campaign, as we literally “Move the Future of Childhood Cancer Research!” cc-TDI’s new location will house the Megan Bugg Global Rhabdomyosarcoma Research Lab, securing Megan’s legacy in supporting rhabdomyosarcoma research.  Our team has been humbled by the outpouring of love and support given in memory of Megan Bugg and we cannot thank the Team Megan Bugg community enough for making this legacy gift possible.  We look forward with heartfelt anticipation to a formal dedication honoring Megan in 2023.

We hope that you will join us in our fundraising efforts and share the importance of Childhood Cancer Awareness as we approach the month of September!  Gifts of any amount will support our laboratory expansion and ongoing research until all children’s cancers are universally survivable.  This is our mission, together. 

Please visit our campaign and join us! Email for the current sponsorship and naming opportunities!

Share this post
Share on facebook
Share on google
Share on twitter
Share on linkedin